LEAC 102

Drug Profile

LEAC 102

Alternative Names: LEAC-102

Latest Information Update: 26 Jul 2016

Price : $50

At a glance

  • Originator Taiwan Biotech Co Ltd
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gastrointestinal cancer

Most Recent Events

  • 21 Jul 2016 Preclinical trials in Gastrointestinal cancer in Taiwan (PO)
  • 21 Jul 2016 Taiwan Leader Biotech plans a phase I/IIa trial for Gastrointestinal cancer in Taiwan and US (NCT02826837)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top